A Patient-Driven Augmented Reality-Based Rehabilitation System to Improve Upper Limb Amputee Outcomes
Launched by INFINITE BIOMEDICAL TECHNOLOGIES · Jul 27, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new rehabilitation system called MyoTrain AR, designed to help people who have lost an arm (specifically below the elbow) improve their ability to use a prosthetic arm. The trial will involve 10 participants who will be divided into two groups. One group will continue with traditional exercises, while the other group will use the MyoTrain AR system for 30 days to train their muscles before getting their prosthetic devices. The goal is to see if using MyoTrain AR helps participants control their prosthetic arm better than the standard exercises.
To join the study, participants must be adults (18 years or older) with a healed limb after amputation and be able to use a specific type of prosthetic arm. Those with certain medical conditions, unhealed wounds, or prior experience with similar technology will not be eligible. Throughout the trial, participants will be assessed on their function before and after the training period, and they will receive their prosthetic devices along with standard occupational therapy afterward. This study aims to improve the overall outcomes for individuals who are adjusting to life with a prosthetic limb.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Trans-radial unilateral limb loss with a healed residual limb
- • Candidate for a 2+ degree-of-freedom (DoF) myoelectric pattern recognition prosthesis as determined by the study prosthetist
- • Fluent in English
- • Age of 18 years or greater
- Exclusion Criteria:
- • Prior experience with pattern recognition control
- • Patients with a residual limb that is unhealed from the amputation surgery
- • Patients with easily damaged or sensitive skin who would not tolerate EMG electrodes
- • Unhealed wounds
- • Significant cognitive deficits as determined upon clinical evaluation
- • Significant neurological deficits as determined upon clinical evaluation
- • Significant physical deficits of the residual limb impacting full participation in the study as determined upon clinical evaluation
- • Uncontrolled pain or phantom pain impactive full participation in the study as determined upon clinical evaluation
- • Serious uncontrolled medical problems as judged by the project therapist
About Infinite Biomedical Technologies
Infinite Biomedical Technologies is a pioneering clinical trial sponsor dedicated to advancing medical innovation through the development of cutting-edge biomedical solutions. With a strong emphasis on research and development, the organization specializes in creating transformative technologies that address unmet clinical needs across various therapeutic areas. By leveraging a multidisciplinary approach and collaborating with leading experts in the field, Infinite Biomedical Technologies aims to enhance patient outcomes and improve healthcare delivery through rigorous clinical trials and evidence-based practices. Committed to ethical standards and regulatory compliance, the company strives to foster trust and transparency in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported